Skip to main content
drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous, fully human anti-CD19 CAR T-cell therapy; patient T cells are engineered to express a chimeric antigen receptor targeting CD19 to deplete CD19+ B-lineage cells and reset humoral immunity in refractory dermatomyositis.
nci_thesaurus_concept_id
C210038
nci_thesaurus_preferred_term
Autologous Anti-CD19 CAR-CD8alpha-CD28-CD3zeta T Cells KYV 101
nci_thesaurus_definition
A preparation of autologous CD4- and CD8-positive T-cells that are transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) consisting of a human single chain variable fragment (scFv) of anti-CD19 and fused to the hinge and transmembrane domains of CD8alpha co-receptor, the cytoplasmic costimulatory domain of human CD28, and the T-cell antigen receptor complex zeta chain (CD3-zeta), with potential immunostimulating activity. Upon transfusion, autologous anti-CD19 CAR-CD8alpha-CD28-CD3zeta T cells KYV 101 recognize and induce selective toxicity and lysis in CD19-expressing B-cells. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies and in certain B-cell-driven autoimmune diseases.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with an anti-CD19 CAR (CD28 costimulatory and CD3ΞΆ signaling domains) recognize CD19 and, upon engagement, become activated to kill CD19+ B-lineage cells (B cells and plasmablasts), depleting autoantibody-producing cells and resetting humoral immunity.
drug_name
KYV-101
nct_id_drug_ref
NCT06298019